Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer
Status:
Terminated
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether or not Aranesp® (Darbepoetin Alfa),
administered every fourth week, is effective in the treatment of blood shortage (anemia)
compared to standard care of treatment (blood transfusions) in patients with anemia due to
hormone refractory prostate cancer.